Transcat (NASDAQ:TRNS) Earns Buy Rating from HC Wainwright

Transcat (NASDAQ:TRNS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $124.00 price objective on the scientific and technical instruments company’s stock. HC Wainwright’s price objective would suggest a potential upside of 12.47% from the company’s previous close.

Separately, TheStreet raised Transcat from a “c+” rating to a “b” rating in a research report on Wednesday, January 31st.

Transcat Stock Up 0.2 %

NASDAQ TRNS traded up $0.17 on Tuesday, reaching $110.25. The company had a trading volume of 8,938 shares, compared to its average volume of 36,741. Transcat has a 52-week low of $74.89 and a 52-week high of $115.41. The company has a quick ratio of 2.81, a current ratio of 3.37 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $973.51 million, a P/E ratio of 84.81 and a beta of 0.59. The company’s fifty day moving average is $108.78 and its 200 day moving average is $101.79.

Transcat (NASDAQ:TRNS) last posted its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.03. Transcat had a net margin of 4.16% and a return on equity of 9.32%. The firm had revenue of $65.17 million during the quarter, compared to analyst estimates of $63.36 million. Sell-side analysts anticipate that Transcat will post 1.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the sale, the chief executive officer now owns 108,478 shares of the company’s stock, valued at approximately $12,073,601.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Lee D. Rudow sold 5,000 shares of Transcat stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $111.30, for a total value of $556,500.00. Following the completion of the transaction, the chief executive officer now owns 108,478 shares in the company, valued at $12,073,601.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Lee D. Rudow sold 2,373 shares of Transcat stock in a transaction dated Saturday, March 30th. The stock was sold at an average price of $111.43, for a total transaction of $264,423.39. Following the completion of the transaction, the chief executive officer now owns 103,688 shares of the company’s stock, valued at approximately $11,553,953.84. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,073 shares of company stock valued at $900,023. 4.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Transcat

Institutional investors and hedge funds have recently made changes to their positions in the business. US Bancorp DE raised its position in shares of Transcat by 137.9% in the first quarter. US Bancorp DE now owns 345 shares of the scientific and technical instruments company’s stock worth $28,000 after buying an additional 200 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of Transcat by 162.3% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,626 shares of the scientific and technical instruments company’s stock worth $92,000 after buying an additional 1,006 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Transcat by 345.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,234 shares of the scientific and technical instruments company’s stock worth $135,000 after buying an additional 957 shares during the last quarter. Barclays PLC increased its holdings in shares of Transcat by 533.1% in the 4th quarter. Barclays PLC now owns 1,912 shares of the scientific and technical instruments company’s stock worth $135,000 after buying an additional 1,610 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Transcat by 219.9% in the fourth quarter. Legal & General Group Plc now owns 2,703 shares of the scientific and technical instruments company’s stock worth $192,000 after buying an additional 1,858 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.